- Home
- WIA vs SCPH Comparison
WIA vs SCPH Comparison
Compare WIA & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIA
- SCPH
- Stock Information
- Founded
- WIA 2003
- SCPH 2013
- Country
- WIA United States
- SCPH United States
- Employees
- WIA N/A
- SCPH N/A
- Industry
- WIA Trusts Except Educational Religious and Charitable
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- WIA Finance
- SCPH Health Care
- Exchange
- WIA Nasdaq
- SCPH Nasdaq
- Market Cap
- WIA 186.8M
- SCPH 160.6M
- IPO Year
- WIA N/A
- SCPH 2017
- Fundamental
- Price
- WIA $8.22
- SCPH $3.28
- Analyst Decision
- WIA
- SCPH Strong Buy
- Analyst Count
- WIA 0
- SCPH 2
- Target Price
- WIA N/A
- SCPH $15.00
- AVG Volume (30 Days)
- WIA 39.2K
- SCPH 251.3K
- Earning Date
- WIA 01-01-0001
- SCPH 03-12-2025
- Dividend Yield
- WIA 12.29%
- SCPH N/A
- EPS Growth
- WIA N/A
- SCPH N/A
- EPS
- WIA N/A
- SCPH N/A
- Revenue
- WIA N/A
- SCPH $30,278,000.00
- Revenue This Year
- WIA N/A
- SCPH $173.14
- Revenue Next Year
- WIA N/A
- SCPH $131.01
- P/E Ratio
- WIA N/A
- SCPH N/A
- Revenue Growth
- WIA N/A
- SCPH 303.87
- 52 Week Low
- WIA $7.56
- SCPH $3.08
- 52 Week High
- WIA $8.91
- SCPH $6.54
- Technical
- Relative Strength Index (RSI)
- WIA 59.46
- SCPH 41.79
- Support Level
- WIA $8.09
- SCPH $3.15
- Resistance Level
- WIA $8.21
- SCPH $3.52
- Average True Range (ATR)
- WIA 0.09
- SCPH 0.18
- MACD
- WIA 0.02
- SCPH -0.00
- Stochastic Oscillator
- WIA 73.33
- SCPH 15.22
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.